Jaspreet Singh, PhD

Biographical Statement

Dr. Jaspreet Singh is a neuroscientist and translational researcher at Henry Ford Health specializing in X-linked adrenoleukodystrophy (X-ALD) and related leukodystrophies. His research program is centered on elucidating the molecular and cellular mechanisms that govern phenotypic variability in X-ALD — specifically the factors that determine whether affected males develop the fatal cerebral form (cALD) or the milder spinal cord phenotype, adrenomyeloneuropathy (AMN) — and on translating these insights into actionable diagnostics and therapies.

Dr. Singh earned his doctoral degree in neuroscience and has built a highly integrated research program that bridges patient-oriented discovery science with experimental therapeutics. A central focus of his laboratory is the identification, discovery and clinical validation of plasma biomarkers that can predict AMN-to-cALD disease progression and serve as pharmacodynamic endpoints in intervention trials. Complementing this effort, his group employs multi-omics platforms — including metabolomics, lipidomics, transcriptomics and proteomics — to characterize the biochemical signatures of leukodystrophy progression in patient-derived samples and experimental models, providing a mechanistic framework for biomarker and therapeutic target discovery.

To model X-ALD pathophysiology with human genetic fidelity, Dr. Singh's laboratory develops and employs induced pluripotent stem cell (iPSC)-derived neural cell models and three-dimensional brain organoids from X-ALD patient lines. Recognizing the complexity and heterogeneity of leukodystrophy phenotypes, Dr. Singh integrates machine learning and computational modeling approaches into his research program. Through multidisciplinary collaborations across neurology, immunology, stem cell biology, genomics and data science, and through active engagement with patient advocacy organizations, Dr. Singh is committed to improving quality of life and long-term outcomes for individuals and families affected by X-ALD and related leukodystrophies.

Research Interests

• X-linked adrenoleukodystrophy (X-ALD) and leukodystrophy disease mechanisms
• Novel drug therapy development targeting VLCFA metabolism, peroxisomal function and neuroinflammation in X-ALD
• Plasma biomarker discovery and clinical validation for prediction of AMN-to-cALD disease progression
• Machine learning and computational models for patient stratification and disease trajectory prediction
• iPSC-derived neural cell models and brain organoids for mechanistic studies of leukodystrophy pathophysiology
• Multi-omics integration: metabolomics, lipidomics, transcriptomics and proteomics in patient-oriented research
• Translational neuroscience and experimental therapeutics for rare neurological diseases

Email: JSINGH2@hfhs.org